1. O82 A phase 1 dose escalation study of PRS-343, a HER2/4–1BB bispecific molecule, in patients with HER2-positive malignancies. (15th April 2020) Authors: Piha-Paul, Sarina; Bendell, Johanna; Tolcher, Anthony; Hurvitz, Sara; Patnaik, Amita; Shroff, Rachna; Pohlmann, Paula; Zettl, Markus; Hahn, Noah; Krishnamurthy, Anuradha; Duerr, Manuela; Mei, Jian; Aviano, Kayti; Yusuf, Rushdia; Matis, Louis; Olwill, Shane; Bruns, Ingmar; Ku, Geoffrey Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 1 Page Start: A1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗